Healthcare provider profile · identity verified

Leo Odle, DO

Internal Medicine · GILBERT, AZ · NPI 1073601415

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Levothyroxine Sodium	Levothyroxine Sodium	379	129
Rosuvastatin Calcium	Rosuvastatin Calcium	369	135
Atorvastatin Calcium	Atorvastatin Calcium	351	126
Amlodipine Besylate	Amlodipine Besylate	245	86
Lisinopril	Lisinopril	205	71
Losartan Potassium	Losartan Potassium	178	64
Metformin Hcl	Metformin Hcl	173	58
Pantoprazole Sodium	Pantoprazole Sodium	169	61
Omeprazole	Omeprazole	147	47
Gabapentin	Gabapentin	145	50
Metoprolol Succinate	Metoprolol Succinate	145	49
Hydrochlorothiazide	Hydrochlorothiazide	111	38
Montelukast Sodium	Montelukast Sodium	102	31
Tamsulosin Hcl	Tamsulosin Hcl	87	32
Famotidine	Famotidine	83	30
Allopurinol	Allopurinol	82	29
Alendronate Sodium	Alendronate Sodium	77	28
Eliquis	Apixaban	77	20
Ozempic	Semaglutide	73	16
Glipizide	Glipizide	68	19
Escitalopram Oxalate	Escitalopram Oxalate	61	20
Trazodone Hcl	Trazodone Hcl	58	18
Clopidogrel	Clopidogrel Bisulfate	56	19
Simvastatin	Simvastatin	55	20
Pravastatin Sodium	Pravastatin Sodium	54	19
Albuterol Sulfate Hfa	Albuterol Sulfate	53	24
Zolpidem Tartrate	Zolpidem Tartrate	53	22
Fluticasone Propionate	Fluticasone Propionate	51	15
Metoprolol Tartrate	Metoprolol Tartrate	50	16
Sertraline Hcl	Sertraline Hcl	49	15
Atenolol	Atenolol	48	18
Alprazolam	Alprazolam	47	18
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	47	19
Jardiance	Empagliflozin	47	14
Lorazepam	Lorazepam	42	13
Methylprednisolone	Methylprednisolone	42	37
Valsartan	Valsartan	40	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	39	14
Duloxetine Hcl	Duloxetine Hcl	38	15
Furosemide	Furosemide	38	17
Quetiapine Fumarate	Quetiapine Fumarate	38	15
Ezetimibe	Ezetimibe	36	12
Tramadol Hcl	Tramadol Hcl	36	19
Citalopram Hbr	Citalopram Hydrobromide	35	suppressed
Glipizide Er	Glipizide	34	11
Synthroid	Levothyroxine Sodium	34	15
Metformin Hcl Er	Metformin Hcl	33	12
Tizanidine Hcl	Tizanidine Hcl	33	13
Carvedilol	Carvedilol	32	13
Buspirone Hcl	Buspirone Hcl	31	12
Venlafaxine Hcl Er	Venlafaxine Hcl	31	suppressed
Nifedipine Er	Nifedipine	30	12
Potassium Chloride	Potassium Chloride	30	13
Ropinirole Hcl	Ropinirole Hcl	30	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	28	11
Oxycodone Hcl	Oxycodone Hcl	27	suppressed
Spironolactone	Spironolactone	27	13
Valacyclovir	Valacyclovir Hcl	27	13
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	25	suppressed
Estradiol	Estradiol	24	11
Lovastatin	Lovastatin	24	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	23	suppressed
Finasteride	Finasteride	23	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	23	suppressed
Bupropion Hcl Sr	Bupropion Hcl	22	suppressed
Cefdinir	Cefdinir	22	19
Prednisone	Prednisone	21	12
Ramipril	Ramipril	21	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	20	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	20	12
Hydralazine Hcl	Hydralazine Hcl	19	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	19	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	18	13
Dicyclomine Hcl	Dicyclomine Hcl	18	suppressed
Donepezil Hcl	Donepezil Hcl	18	suppressed
Ipratropium Bromide	Ipratropium Bromide	18	suppressed
Memantine Hcl	Memantine Hcl	18	suppressed
Mounjaro	Tirzepatide	18	suppressed
Testosterone Cypionate	Testosterone Cypionate	18	suppressed
Diazepam	Diazepam	17	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	17	suppressed
Terazosin Hcl	Terazosin Hcl	17	suppressed
Azithromycin	Azithromycin	16	12
Celecoxib	Celecoxib	16	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	15	suppressed
Ibuprofen	Ibuprofen	15	suppressed
Premarin	Estrogens, Conjugated	15	suppressed
Promethazine Hcl	Promethazine Hcl	15	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	14	12
Irbesartan	Irbesartan	14	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Symbicort	Budesonide/Formoterol Fumarate	14	suppressed
Bupropion Hcl	Bupropion Hcl	13	suppressed
Cyanocobalamin Injection	Cyanocobalamin (Vitamin B-12)	13	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	13	suppressed
Glimepiride	Glimepiride	13	suppressed
Lansoprazole	Lansoprazole	13	suppressed
Terbinafine Hcl	Terbinafine Hcl	13	suppressed
Tresiba Flextouch U-100	Insulin Degludec	13	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	13	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	13	suppressed
Anastrozole	Anastrozole	12	suppressed
Eszopiclone	Eszopiclone	12	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	12	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	12	suppressed
Meloxicam	Meloxicam	12	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	12	suppressed
Clonazepam	Clonazepam	11	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	11	suppressed
Lamotrigine	Lamotrigine	11	suppressed
Mometasone Furoate	Mometasone Furoate	11	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	11	suppressed
Rybelsus	Semaglutide	11	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed
Xarelto	Rivaroxaban	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error